The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Epcoritamab vs SoC (SCHOLAR-5 cohort) in patients with R/R FL
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, provides an insight into an unanchored, matching-adjusted indirect comparison (MAIC) comparing the efficacy of epcoritamab to the standard of care (SoC) in patients with relapsed/refractory (R/R) follicular lymphoma (FL). The data for the SoC group came from the SCHOLAR-5 real-world cohort, and the data for the epcoritamab group came from the pivotal EPCORE NHL-1 trial (NCT03625037). The findings of this analysis suggest that treatment with epcoritamab results in a higher overall response rate (ORR) and confers a survival benefit. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jannsen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GenMab: Consultancy, Honoraria; Pierre Fabre: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria.
